Financial PerformanceProtara Therapeutics has a strong cash position with approximately $145.6 million in cash, cash equivalents, and investments, which supports its ongoing clinical trials and operations.
Product PotentialThere is a compelling case for Protara's TARA-002 as a better option to circumvent BCG supply issues due to its similar mechanism of action as bacterial immunopotentiators.
ValuationAnalyst's valuation indicates a price target of $21, driven by the potential of TARA-002 in different medical applications and other assets.